Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2013, Article ID 308052, 10 pages
http://dx.doi.org/10.1155/2013/308052
Review Article

Methamphetamine and Parkinson's Disease

1Instituto Cajal (CSIC), Avenida Doctor Arce 37, 28002 Madrid, Spain
2CIBERNED, Instituto de Salud Carlos III, Madrid, Spain
3Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

Received 20 August 2012; Accepted 22 October 2012

Academic Editor: José Manuel Fuentes Rodríguez

Copyright © 2013 Noelia Granado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Thomas and M. F. Beal, “Parkinson's disease,” Human Molecular Genetics, vol. 16, no. 2, pp. R183–R194, 2007. View at Google Scholar
  2. UNODC, “World drug report,” Tech. Rep. E. 12.XI. 1, United Nations publication, 2012. View at Google Scholar
  3. U. D. McCann, H. Kuwabara, A. Kumar et al., “Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users,” Synapse, vol. 62, no. 2, pp. 91–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. E. Rusyniak, “Neurologic manifestations of chronic methamphetamine abuse,” Neurologic Clinics, vol. 29, no. 3, pp. 641–655, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ares-Santos, N. Granado, and Oliva, “Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine,” Neurological Diseases, vol. 45, pp. 810–820, 2012. View at Google Scholar
  6. N. Granado, S. Ares-Santos, E. O'Shea, C. Vicario-Abejón, M. I. Colado, and R. Moratalla, “Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine,” Neurotoxicity research, vol. 18, no. 1, pp. 48–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Granado, S. Ares-Santos, I. Oliva et al., “Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA,” Neurobiology of Disease, vol. 42, no. 3, pp. 391–403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. T. R. Guilarte, M. K. Nihei, J. L. McGlothan, and A. S. Howard, “Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity,” Neuroscience, vol. 122, no. 2, pp. 499–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. I. N. Krasnova and J. L. Cadet, “Methamphetamine toxicity and messengers of death,” Brain Research Reviews, vol. 60, no. 2, pp. 379–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Ricaurte, C. R. Schuster, and L. S. Seiden, “Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study,” Brain Research, vol. 193, no. 1, pp. 153–163, 1980. View at Publisher · View at Google Scholar · View at Scopus
  11. L. S. Seiden and K. E. Sabol, “Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction,” NIDA research monograph, vol. 163, pp. 251–276, 1996. View at Google Scholar · View at Scopus
  12. N. Granado, I. Escobedo, E. O'Shea, M. I. Colado, and R. Moratalla, “Early loss of dopaminergic terminals in striosomes after MDMA administration to mice,” Synapse, vol. 62, no. 1, pp. 80–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Granado, E. O'Shea, J. Bove, M. Vila, M. I. Colado, and R. Moratalla, “Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice,” Journal of Neurochemistry, vol. 107, no. 4, pp. 1102–1112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. O'Callaghan and D. B. Miller, “Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse,” Journal of Pharmacology and Experimental Therapeutics, vol. 270, no. 2, pp. 741–751, 1994. View at Google Scholar · View at Scopus
  15. N. Granado, I. Lastres-Becker, S. Ares-Santos et al., “Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum,” Glia, vol. 59, pp. 1850–1863, 2011. View at Google Scholar
  16. G. U. Höglinger, P. Rizk, M. P. Muriel et al., “Dopamine depletion impairs precursor cell proliferation in Parkinson disease,” Nature Neuroscience, vol. 7, no. 7, pp. 726–735, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Bezard, I. Gerlach, R. Moratalla, C. E. Gross, and R. Jork, “5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease,” Neurobiology of Disease, vol. 23, no. 1, pp. 77–86, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. P. Melega, M. J. Raleigh, D. B. Stout, G. Lacan, S. C. Huang, and M. E. Phelps, “Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey,” Brain Research, vol. 766, no. 1-2, pp. 113–120, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Huot and A. Parent, “Dopaminergic neurons intrinsic to the striatum,” Journal of Neurochemistry, vol. 101, no. 6, pp. 1441–1447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Darmopil, V. C. Muñetón-Gómez, M. L. De Ceballos, M. Bernson, and R. Moratalla, “Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA,” European Journal of Neuroscience, vol. 27, no. 3, pp. 580–592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Espadas, S. Darmopil, E. Vergaño-Vera et al., “L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function,” Neurobiology of Disease, vol. 48, pp. 271–281, 2012. View at Google Scholar
  22. L. C. Schmued and J. F. Bowyer, “Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants,” Brain Research, vol. 759, no. 1, pp. 135–140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Hirata and J. L. Cadet, “p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies,” Journal of Neurochemistry, vol. 69, no. 2, pp. 780–790, 1997. View at Google Scholar · View at Scopus
  24. P. K. Sonsalla, N. D. Jochnowitz, G. D. Zeevalk, J. A. Oostveen, and E. D. Hall, “Treatment of mice with methamphetamine produces cell loss in the substantia nigra,” Brain Research, vol. 738, no. 1, pp. 172–175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. H. I. Hurtig, J. Q. Trojanowski, J. Galvin et al., “Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease,” Neurology, vol. 54, no. 10, pp. 1916–1921, 2000. View at Google Scholar · View at Scopus
  26. M. G. Murer and R. Moratalla, “Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation,” Frontiers in Neuroanatomy, vol. 5, p. 51, 2011. View at Google Scholar
  27. R. Moratalla, M. Xu, S. Tonegawa, and A. M. Graybiel, “Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14928–14933, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. N. M. White and N. Hiroi, “Preferential localization of self-stimulation sites in striosomes/patches in the rat striatum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6486–6491, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Crittenden, I. Cantuti-Castelvetri, E. Saka et al., “Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2892–2896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Iravani, E. Syed, M. J. Jackson, L. C. Johnston, L. A. Smith, and P. Jenner, “A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets,” European Journal of Neuroscience, vol. 21, no. 4, pp. 841–854, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Figueredo-Cardenas, C. L. Harris, K. D. Anderson, and A. Reiner, “Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types,” Experimental Neurology, vol. 149, no. 2, pp. 356–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Hedreen and S. E. Folstein, “Early loss of neostriatal striosome neurons in Huntington's disease,” Journal of Neuropathology and Experimental Neurology, vol. 54, no. 1, pp. 105–120, 1995. View at Google Scholar · View at Scopus
  33. R. E. Burke and K. G. Baimbridge, “Relative loss of the striatal striosome compartment, defined by calbindin-D(28k) immunostaining, following developmental hypoxic-ischemic injury,” Neuroscience, vol. 56, no. 2, pp. 305–315, 1993. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Medina, G. Figueredo-Cardenas, J. D. Rothstein, and A. Reiner, “Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS-resistant brain stem motor cell groups,” Experimental Neurology, vol. 142, no. 2, pp. 287–295, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Cadet and C. Brannock, “Free radicals and the pathobiology of brain dopamine systems,” Neurochemistry International, vol. 32, no. 2, pp. 117–131, 1998. View at Google Scholar
  36. P. Pacher, J. S. Beckman, and L. Liaudet, “Nitric oxide and peroxynitrite in health and disease,” Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Itzhak and C. Achat-Mendes, “Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men',” IUBMB Life, vol. 56, no. 5, pp. 249–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Z. Imam, G. D. Newport, Y. Itzhak et al., “Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase,” Journal of Neurochemistry, vol. 76, no. 3, pp. 745–749, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Itzhak, J. L. Martin, and S. F. Ali, “Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice,” Synapse, vol. 34, no. 4, pp. 305–312, 1999. View at Google Scholar
  40. J. F. Bowyer, B. Robinson, S. Ali, and L. C. Schmued, “Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure,” Synapse, vol. 62, no. 3, pp. 193–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. X. Deng and J. L. Cadet, “Methamphetamine administration causes overexpression of nNOS in the mouse striatum,” Brain Research, vol. 851, no. 1-2, pp. 254–257, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, and M. G. Caron, “Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter,” Journal of Neuroscience, vol. 18, no. 13, pp. 4861–4869, 1998. View at Google Scholar · View at Scopus
  43. S. Ares-Santos, N. Granado, and R. Moratalla, “Role of dopamine receptors in the neurotoxicity of methamphetamine,” Journal of Internal Medicine. In press.
  44. A. B. Martín, E. Fernandez-Espejo, B. Ferrer et al., “Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors,” Neuropsychopharmacology, vol. 33, no. 7, pp. 1667–1679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Granado, O. Ortiz, L. M. Suárez et al., “D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif268 expression in the hippocampus,” Cerebral Cortex, vol. 18, no. 1, pp. 1–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. O. Ortiz, J. M. Delgado-García, I. Espadas et al., “Associative learning and CA3-CA1 synaptic plasticity are impaired in D 1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice,” Journal of Neuroscience, vol. 30, no. 37, pp. 12288–12300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Madroñal, A. Gruart, O. Valverde, I. Espadas, R. Moratalla, and J. M. Delgado-García, “Involvement of cannabinoid CB1 receptor in associative learning and in hippocampal CA3-CA1 synaptic plasticity,” Cerebral Cortex, vol. 22, no. 3, pp. 550–566, 2012. View at Publisher · View at Google Scholar
  48. Y. J. Chen, Y. L. Liu, Q. Zhong et al., “Tetrahydropalmatine protects against methamphetamine-induced spatial learning and memory impairment in mice,” Neuroscience Bulletin, vol. 28, no. 3, pp. 222–232, 2012. View at Google Scholar
  49. J. Gonçalves, S. Baptista, M. V. Olesen et al., “Methamphetamine-induced changes in the mice hippocampal neuropeptide Y system: implications for memory impairment,” Journal of Neurochemistry, vol. 123, no. 6, pp. 1041–1053, 2012. View at Google Scholar
  50. T. R. Guilarte, “Is methamphetamine abuse a risk factor in Parkinsonism?” NeuroToxicology, vol. 22, no. 6, pp. 725–731, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Thrash, K. Thiruchelvan, M. Ahuja, V. Suppiramaniam, and M. Dhanasekaran, “Methamphetamine-induced neurotoxicity: the road to Parkinson's disease,” Pharmacological Reports, vol. 61, no. 6, pp. 966–977, 2009. View at Google Scholar · View at Scopus
  52. J. M. Wilson, K. S. Kalasinsky, A. I. Levey et al., “Striatal dopamine nerve terminal markers in human, chronic methamphetamine users,” Nature Medicine, vol. 2, no. 6, pp. 699–703, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. U. D. McCann, D. F. Wong, F. Yokoi, V. Villemagne, R. F. Dannals, and G. A. Ricaurte, “Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428,” Journal of Neuroscience, vol. 18, no. 20, pp. 8417–8422, 1998. View at Google Scholar · View at Scopus
  54. N. D. Volkow, L. Chang, G. J. Wang et al., “Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence,” Journal of Neuroscience, vol. 21, no. 23, pp. 9414–9418, 2001. View at Google Scholar · View at Scopus
  55. N. D. Volkow, L. Chang, G. J. Wang et al., “Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers,” American Journal of Psychiatry, vol. 158, no. 3, pp. 383–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. N. D. Volkow, L. Chang, G. J. Wang et al., “Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers,” American Journal of Psychiatry, vol. 158, no. 3, pp. 377–382, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Chang, D. Alicata, T. Ernst, and N. Volkow, “Structural and metabolic brain changes in the striatum associated with methamphetamine abuse,” Addiction, vol. 102, supplement 1, pp. 16–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Sekine, Y. Ouchi, N. Takei et al., “Brain serotonin transporter density and aggression in abstinent methamphetamine abusers,” Archives of General Psychiatry, vol. 63, no. 1, pp. 90–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. P. S. Fitzmaurice, J. Tong, M. Yazdanpanah, P. P. Liu, K. S. Kalasinsky, and S. J. Kish, “Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 703–709, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Mirecki, P. Fitzmaurice, L. Ang et al., “Brain antioxidant systems in human methamphetamine users,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1396–1408, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Sekine, Y. Ouchi, G. Sugihara et al., “Methamphetamine causes microglial activation in the brains of human abusers,” Journal of Neuroscience, vol. 28, no. 22, pp. 5756–5761, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. O. Kitamura, T. Takeichi, E. L. Wang, I. Tokunaga, A. Ishigami, and S. I. Kubo, “Microglial and astrocytic changes in the striatum of methamphetamine abusers,” Legal Medicine, vol. 12, no. 2, pp. 57–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988. View at Google Scholar · View at Scopus
  64. E. C. Hirsch and S. Hunot, “Neuroinflammation in Parkinson's disease: a target for neuroprotection?” The Lancet Neurology, vol. 8, no. 4, pp. 382–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Sekine, Y. Minabe, Y. Ouchi et al., “Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms,” American Journal of Psychiatry, vol. 160, no. 9, pp. 1699–1701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. P. M. Thompson, K. M. Hayashi, S. L. Simon et al., “Structural abnormalities in the brains of human subjects who use methamphetamine,” Journal of Neuroscience, vol. 24, no. 26, pp. 6028–6036, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Chang, T. Ernst, O. Speck et al., “Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users,” Psychiatry Research, vol. 114, no. 2, pp. 65–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Moszczynska, P. Fitzmaurice, L. Ang et al., “Why is parkinsonism not a feature of human methamphetamine users?” Brain, vol. 127, no. 2, pp. 363–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. M. P. Caligiuri and C. Buitenhuys, “Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?” Neuropsychopharmacology, vol. 30, no. 12, pp. 2125–2134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Bernheimer, W. Birkmayer, and O. Hornykiewicz, “Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations,” Journal of the Neurological Sciences, vol. 20, no. 4, pp. 415–455, 1973. View at Publisher · View at Google Scholar · View at Scopus
  71. S. J. Kish, K. Shannak, and O. Hornykiewicz, “Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications,” The New England Journal of Medicine, vol. 318, no. 14, pp. 876–880, 1988. View at Google Scholar · View at Scopus
  72. R. C. Callaghan, J. K. Cunningham, G. Sajeev, and S. J. Kish, “Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders,” Movement Disorders, vol. 25, no. 14, pp. 2333–2339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. R. C. Callaghan, J. K. Cunningham, J. Sykes, and S. J. Kish, “Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs,” Drug and Alcohol Dependence, vol. 120, pp. 35–40, 2012. View at Google Scholar